Form 4: Phathom Pharmaceuticals Director James N. Topper Reports Stock Purchases

Director James N. Topper reports multiple purchases of Phathom Pharmaceuticals (PHAT) common stock through various entities.

Summary

• James N. Topper, a director of Phathom Pharmaceuticals, reported several transactions involving the company's common stock.
• On May 9, 2025, 33,376 shares were purchased at a weighted average price of $3.1928, with prices ranging from $2.575 to $3.57.
• An additional 2,226 shares were purchased on May 9, 2025, at a weighted average price of $3.6177, with prices ranging from $3.58 to $3.75.
• On May 12, 2025, 12,601 shares were purchased at a weighted average price of $3.0395, with prices ranging from $2.825 to $3.15.
• These shares were purchased indirectly through entities such as Frazier Life Sciences X, L.P., Frazier Life Sciences IX, L.P., FHMLS IX, L.L.C, and Topper Group III LLC.
• Topper disclaims beneficial ownership of shares held by Frazier Life Sciences X, L.P., Frazier Life Sciences IX, L.P., and FHMLS IX, L.L.C. except to the extent of his pecuniary interest.
• Topper is a manager of Topper Group III LLC and has voting and investment power over the securities held by that entity.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a report of stock purchases by a director, which could be seen as positive but requires further context.

Positives

• The director's purchases could be interpreted as a sign of confidence in the company's future prospects.

Industry Context

Insider transactions are closely watched by investors as they can provide insights into a company's prospects, although they don't guarantee future performance.

Stakeholder Impact

• Shareholders may view the director's stock purchases as a positive signal.

Key Dates

Keywords

Phathom Pharmaceuticals, insider trading, Form 4, stock purchase, James N. Topper, director